Acute Heart Failure - Drug Pipeline Analysis and Market Forecasts to 2016

18 Mar 2010 • by Natalie Aster
GlobalData, the industry analysis specialist’s new report, “Acute Heart Failure - Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global acute heart failure market (AHF). The report identifies the key trends shaping and driving the market, and provides insight into the competitive landscape and the emerging players expected to bring a significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight into the pipeline products within the AHF sector.

The Acute Heart Failure Market is Forecast to Show Slow Growth Until 2016

GlobalData predicts the AHF therapeutics market to be valued at $2.3 billion in 2009. The market is estimated to grow up to $2.6 billion in 2016, with a CAGR of 2.1%. Growth in the AHF market is driven by the increasing number of patients and the launch of new promising drugs during the next few years. The US is the largest market for AHF and it contributes to approximately 50% of the global market.

The Acute Heart Failure Market Has High Unmet Need In Terms Of Efficacy

The current AHF market is underserved by the existing treatment options. GlobalData’s analysis revealed that the current unmet need in the AHF market is approximately 58%. A major reason for this is attributed to the low efficacy aspects of the available treatment options. The value of unmet need in 2009 was calculated to be $1.3 billion. This suggests that there is huge untapped potential in the current AHF market. And this could be captured by novel molecules, targeted to fulfill the current void left by the existing treatment options. Thus the AHF market has high potential for further research and development activities.

The Acute Heart Failure Market Growth is Driven By Increasing Number of Patients and Launch of New Treatment Options in The Next Few Years

Elderly people are at greater risk of developing AHF. More than half of the current patient population for AHF includes people aged over 50. A UN study of the global aging population reveals that the growth rate for the elderly population (1.9%) is significantly higher than the growth rate for the total population (1.2%). Thus an increase in the incidence for AHF could be expected in the next few decades.

There are limited treatment options for the treatment of AHF. Existing therapies are dominated by generic drugs. Even though the present developmental pipeline for AHF is relatively weak in terms of the number of molecules, there exist promising molecules in both the Phase II and III stages of the pipeline. These molecules comprise of both first-in-class mechanisms of action and existing mechanisms of action (me-toos) and this is likely to address the void left by the current therapeutic options in terms of both safety and efficacy. Hence positive outcomes for these developmental drugs will cause a shift in the prescription trend, switching the therapeutic options from current generic drugs to the new upcoming drugs with innovative mechanism of action.

About GlobalData

GlobalData is an industry analysis specialist company providing business information products and services.

Our highly qualified team of Analysts, Researchers, and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyze and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.